C-Reactive Protein (CRP) Is Essential for Efficient Systemic Transduction of Recombinant Adeno-Associated Virus Vector 1 (rAAV-1) and rAAV-6 in Mice

Heparin-binding correlates with increased efficiency of AAV1- and AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction

(2012) A L H Arnett et al.   GENE THERAPY

Humoral and Cellular Capsid-Specific Immune Responses to Adeno-Associated Virus Type 1 in Randomized Healthy Donors

(2012) P. Veron et al.   JOURNAL OF IMMUNOLOGY

Human Galectin 3 Binding Protein Interacts with Recombinant Adeno-Associated Virus Type 6

(2012) J. Denard et al.   JOURNAL OF VIROLOGY

Glycan Binding Avidity Determines the Systemic Fate of Adeno-Associated Virus Type 9

(2012) S. Shen et al.   JOURNAL OF VIROLOGY

Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells

(2011) B Cheng et al.   GENE THERAPY

TerminalN-Linked Galactose Is the Primary Receptor for Adeno-associated Virus 9

(2011) Shen Shen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Potential Role of Distinctively Delayed Blood Clearance of Recombinant Adeno-associated Virus Serotype 9 in Robust Cardiac Transduction

(2011) Nicole M Kotchey et al.   MOLECULAR THERAPY

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

(2011) Chen Ling et al.   Jove-Journal of Visualized Experiments

Comparative Cardiac Gene Delivery of Adeno-Associated Virus Serotypes 1-9 reveals that AAV6 Mediates the Most Efficient Transduction in Mouse Heart

(2010) Carmela Zincarelli et al.   CTS-Clinical and Translational Science

Gene transfer into human cord blood−derived CD34+ cells by adeno-associated viral vectors

(2010) Natascha K. Schuhmann et al.   EXPERIMENTAL HEMATOLOGY

Human Hepatocyte Growth Factor Receptor Is a Cellular Coreceptor for Adeno-Associated Virus Serotype 3

(2010) Chen Ling et al.   HUMAN GENE THERAPY

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

(2010) Sylvie Boutin et al.   HUMAN GENE THERAPY

No Reduction of Atherosclerosis in C-reactive Protein (CRP)-deficient Mice

(2010) Daniel Teupser et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Transient Transfection Methods for Clinical Adeno-Associated Viral Vector Production

(2009) J. Fraser Wright   HUMAN GENE THERAPY

Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle

(2009) Aravind Asokan et al.   NATURE BIOTECHNOLOGY

Adeno-associated virus-2 and its primary cellular receptor—Cryo-EM structure of a heparin complex

(2009) Jason O'Donnell et al.   VIROLOGY

Immunity to adeno-associated virus vectors in animals and humans: a continued challenge

(2008) A K Zaiss et al.   GENE THERAPY

Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors

(2008) A. K. Zaiss et al.   JOURNAL OF VIROLOGY

Systemic Microdystrophin Gene Delivery Improves Skeletal Muscle Structure and Function in Old Dystrophic mdx Mice

(2008) Paul Gregorevic et al.   MOLECULAR THERAPY

Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection

(2008) Carmela Zincarelli et al.   MOLECULAR THERAPY